Full-Time

Senior Imaging Science Engineer

Multiple Teams

Posted on 7/26/2025

Calyxo

Calyxo

201-500 employees

Develops and markets kidney stone devices

Compensation Overview

$160k - $200k/yr

+ Variable Incentive Plan + Stock Options

No H1B Sponsorship

Pleasanton, CA, USA

In Person

On-site 5 days a week.

Category
Medical, Clinical & Veterinary (1)
Required Skills
CAD
Python
SolidWorks
Requirements
  • MS in Imaging Science, Optical Engineering, Electrical Engineering, Physics or a related technical field. PhD preferred and 4+ years of experience in product development related to camera and illumination system design/characterization.
  • Deep technical expertise in camera and illumination system quantitative analysis, including relevant standards (e.g. ISO 8600, 12233, 14524 and 15739) and colorimetry, including practical application of CIE ΔE and ΔC measurement.
  • Practical experience in hands-on laboratory optics, including use of optical test targets, backlights, optomechanics, meters, sensors and other test equipment.
  • Experience performing photometric and radiometric quantitative analyses of illumination systems, including power meters, spectroradiometers and spectrophotometers.
  • Practical working knowledge of analog and digital electronics fundamentals.
  • Experience using Imatest software for image quality assessment.
  • Proficiency in Python or alternative scripting language for image/video analysis, hardware control and test automation strongly preferred.
  • Expertise in optical/optomechanical component and system design. ZEMAX (or alternative ray-tracing software) and SolidWorks (or alternative CAD software) preferred.
  • Experience leading external vendors and contract manufacturers in the development of custom imaging solutions.
  • Strong problem-solving skills and experience working as part of multifunctional technical project teams through all development lifecycle phases.
  • Experience in requirements definition, design reviews, change management and risk control.
  • Excellent technical writing and verbal communication skills are a must.
  • Ability to work independently or in a team setting required.
  • Must be self-directed, self-motivated and be able to multi-task in a fast-paced environment with multiple priorities.
  • Knowledge and ability to interpret and follow applicable regulations, guidelines, and policy statements is required. Must have experience working under quality systems designed to meet governmental regulations such as FDA QSR, ISO 13485, and the MDD.
  • Ability to travel domestically and internationally up to 10% of the time.
Responsibilities
  • Design camera and illumination optical systems/subsystems for endoscopy and perform detailed quantitative analyses of their imaging & video performance.
  • Work with cross-functional teams to define requirements for image and video quality.
  • Drive in-process and end-of-line optical test methodology used in component and device manufacturing.
  • Work with clinical engineering and product management to translate user feedback on visualization quality into bench-testable design improvements.
  • Organize design reviews to ensure optimal imaging design performance across disposable instruments, capital hardware, and software interfaces.
  • Create change orders, test protocols/reports, and design documents.
  • Complete Design Verification testing and risk management activities.
  • Interact with suppliers and internal operations representatives to perform root cause investigation, component lifecycle management and continuous improvement.
  • Create, operate and maintain an optical test bench and testing laboratory environment complying with Calyxo’s internal Quality Management System.
  • Contribute to the technology roadmap for visualization and related research endeavors.
  • Contribute to a culture of continuous improvement and innovation among engineering and cross-functional teams.
  • Collaborate with cross-functional teams to bring prototypes to the market.
  • Mentor junior and non-specialist engineering talent, promoting a collaborative and high-performance work environment.
Desired Qualifications
  • Experience and involvement with MDRs, IDEs, and 510(k) filings is preferred.

Calyxo, Inc. develops medical devices for kidney stone treatment. Its products are designed for use by urologists in hospitals and clinics to treat kidney stones more effectively, prioritizing patient safety and efficient procedures. The company works closely with leading U.S. urologists to translate clinical needs into devices, focusing on making treatments safer and easier for clinicians. Unlike some competitors, Calyxo emphasizes clinician collaboration and proven clinical relevance in its device development, backed by leadership with startup and product-launch experience. The goal is to improve patient care by delivering advanced devices that help urologists achieve better clinical outcomes and expand the devices’ reach through commercialization to healthcare providers.

Company Size

201-500

Company Stage

Series F

Total Funding

$137.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Series F raised $40M led by Ally Bridge Group and Janus Henderson Investors.
  • CVAC system treated over 40,000 patients, advancing toward standard of care.
  • ASPIRE study at AUA showed superior clearance independent of stone burden in 101 patients.

What critics are saying

  • Boston Scientific's LithoClast Trilogy erodes market share via hospital contracts in 12-24 months.
  • Cook Medical's NGage basket undercuts CVAC pricing by 30% in 12-18 months.
  • FDA Class I recall triggers withdrawal due to 5% ureteral perforation risks in 3-9 months.

What makes Calyxo unique

  • CVAC System integrates ureteroscopy, laser lithotripsy, irrigation, and aspiration in one device.
  • SURE procedure with CVAC achieves 97% volumetric stone clearance versus standard URS.
  • Redesigned CVAC received FDA clearance in March 2024 for minimally invasive treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

8%
StreetInsider
Apr 14th, 2026
Calyxo raises $40M Series F as CVAC kidney stone system treats 40,000 patients

Calyxo, a medical device company focused on kidney stone treatment, has closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors. Questa Capital, Avidity Partners and CRG also participated. The funding follows a milestone of 40,000 patients treated with Calyxo's CVAC System, an aspiration-based stone removal device. The system uses irrigation and vacuum aspiration to continuously clear stone fragments during procedures, enabling more complete stone clearance. Proceeds will support commercial expansion, clinical evidence generation through ongoing studies evaluating long-term outcomes, and continued innovation in kidney stone care. The CVAC System received FDA clearance in 2024 and is positioned as an all-in-one solution for minimally invasive kidney stone removal.

Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

FinSMEs
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.

INACTIVE